Vaxcyte, Inc. (5VA.MU)
Munich - Munich Delayed Price. Currency in EUR
Add to watchlist
As of 08:05AM CEST. Market open.
| Previous Close | 61.50 |
| Open | 62.50 |
| Bid | 62.50 x N/A |
| Ask | 63.00 x N/A |
| Day's Range | 62.50 - 62.50 |
| 52 Week Range | 41.40 - 74.50 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 6.931B |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.84 |
| Earnings Date | May 08, 2024 - May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GuruFocus.comInsider Sale at Vaxcyte Inc: COO Jim Wassil Sells 3,000 Shares
On May 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), sold 3,000 shares of the company.
GlobeNewswireVaxcyte to Present at the 23rd Annual Needham Virtual Healthcare Conference
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media se
GuruFocus.comSutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic Advances
Full Year Earnings Reveal Strong Revenue Growth but Operational Challenges Persist
© 2024 Yahoo. All rights reserved.